文献速递造血干细胞移植与细胞治疗血栓与止血

多中心前瞻性研究揭示造血干细胞移植相关血栓性微血管病的真实发病率与不良结局

A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.
PubMed 文献 · Blood Adv · 2021-01-01

该多中心前瞻性研究在13个儿科中心对614例HSCT患者自预处理至+100天采用简易策略筛查TA-TMA,诊断98例(16%),中位诊断时间移植后22天。TA-TMA患者血流感染、总住院日和ICU天数显著增加,总生存率显著降低(78% vs 93%),支持系统筛查的必要性与可行性。

要点

  • 儿科HSCT患者TA-TMA前瞻性筛查发病率为16%,高于既往回顾性研究。
  • TA-TMA患者血流感染、住院及ICU天数显著增加,总生存率显著降低。
  • 简易筛查策略可行,支持在移植中心系统开展TA-TMA筛查。

核心结论

  • 系统筛查下TA-TMA发病率达16%,且与感染、住院资源使用增加和生存率降低显著相关。
  • 简易筛查策略在多中心儿科HSCT人群中可行且有效,支持常规筛查。

研究设计与样本

  • 多中心前瞻性队列研究,13个儿科中心,614例HSCT患者(男性359例,58%)。
  • 自预处理开始至移植后+100天采用简易低成本策略前瞻性筛查TA-TMA。

主要发现

  • 98例(16%)诊断为TA-TMA,中位诊断时间为移植后22天(IQR 14-44)。
  • TA-TMA组血流感染38%(37/98) vs 无TA-TMA组21%(107/51),P ≤ .001。
  • TA-TMA组平均总住院日68天(95%CI 63-74) vs 43天(95%CI 41-45),P ≤ .001。
  • TA-TMA组ICU天数10.1天(95%CI 6.4-14) vs 1.6天(95%CI 1.1-2.2),P ≤ .001。
  • 无TA-TMA组总生存率93%(490/516) vs TA-TMA组78%(76/98),P ≤ .001。

关键数值与推荐

  • TA-TMA诊断标准:7项实验室/临床标志物中至少4项同时阳性,或组织病理学显示TA-TMA。

临床怎么用

  • 对儿科HSCT患者自预处理至+100天采用简易策略系统筛查TA-TMA。
  • 对筛查阳性患者加强感染监测与资源管理,警惕住院及ICU需求增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation (HSCT). A single-center prospective screening study has shown that the incidence of TA-TMA is much higher than prior retrospective studies that did not systematically screen. These data have not been replicated in a multicenter study. Our objective was to determine the incidence and risk factors for TA-TMA and compare outcomes of pediatric HSCT patients with and without TA-TMA. Patients were prospectively screened for TA-TMA at participating centers using a simple to implement and inexpensive strategy from the start of the preparative regimen through day +100. TA-TMA was diagnosed if ≥4 of 7 laboratory/clinical markers diagnostic for TA-TMA were present concurrently or if tissue histology showed TA-TMA. A total of 614 patients (359 males; 58%) received prospective TA-TMA screening at 13 pediatric centers. TA-TMA was diagnosed in 98 patients (16%) at a median of 22 days (interquartile range, 14-44) posttransplant. Patients with TA-TMA had significantly increased bloodstream infections (38% [37/98] vs 21% [107/51], P ≤ .001), mean total hospitalization days (68; 95% confidence interval [CI], 63-74 vs 43; 95% CI, 41-45; P ≤ .001), and number of days spent in the intensive care unit (10.1; 95% CI, 6.4-14; vs 1.6; 95% CI, 1.1-2.2; P ≤ .001) in the first 100 days after HSCT compared with patients without TA-TMA. Overall survival was significantly higher in patients without TA-TMA (93%; 490/516) compared with patients with TA-TMA (78%; 76/98) (P ≤ .001). These data support the need for systematic screening for TA-TMA and demonstrate the feasibility and efficacy of an easy to implement strategy to do so.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dandoy CE, Rotz S, Alonso PB, et al. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv. 2021. PMID: 33570619. doi:10.1182/bloodadvances.2020003455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。